• PDF / 174,871 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 48 Downloads / 170 Views

DOWNLOAD

REPORT

---

1 S

Chemotherapy-induced peripheral neuropathy and lack of efficacy: 3 case reports In a case series, a 42‑year‑old man, a 65‑year‑old man and a 40‑year‑old man were described, who developed chemotherapy-induced peripheral neuropathy (CIPN) during treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (one patient), cisplatin and doxorubicin (one patient) and cisplatin and fluorouracil (one patient) for gastric and testicular diffuse large B‑cell lymphoma (DLBCL), low‑grade central osteosarcoma of the left tibia and metastatic adenocarcinoma of the stomach, respectively. Additionally, all three men exhibited lack of efficacy while receiving duloxetine for CIPN [dosages, routes and duration of treatments to reactions onsets not stated]. Case 1: A 42‑year‑old man, who had gastric and testicular DLBCL, was scheduled to receive six cycles of rituximab, cyclophosphamide, doxorubicin [doxorubicin hydrochloride], vincristine [vincristine sulfate], and prednisone (R-CHOP regimen). He tolerated first two cycles of chemotherapy very well. A few days following the administration of third cycle of chemotherapy, he developed pain in the bilateral upper and lower limbs which had typical glove and stocking pattern of distribution. Pain was burning in character, severe in intensity (numerical rating scale (NRS) 8/10), and worse at night. The pain aggravated while sitting or lying down, but relieved by standing or walking. The pain was accompanied by tingling and numbness of both hands and feet. He was prescribed duloxetine 30mg at bed time for 3 days. It was recommended to increase the dosage to 30mg twice a day if adequate pain relief was not obtained. On follow‑up after 1 week, he had inadequate pain relief with the prescribed medications and his NRS was still 7/10. After evaluation, it was decided to increase the dosage of duloxetine to 60mg twice a day. On follow‑up after 1 week, his pain persisted with the same intensity, despite increasing the dosage of duloxetine to a maximum for 1 week. Due to the presence of severe neuropathic pain, the administration of next cycle of chemotherapy was delayed. Subsequently, it was decided to manage the refractory CIPN with scrambler therapy. A total of 12 sessions of scrambler therapy were administered with continuous recording of NRS. The NRS score was 7/10 on day 1, 4/10 on day 5 and 2/10 on day 10. The NRS scores showed an adequate pain relief following the initiation of scrambler therapy. Case 2: A 65‑year‑old man, who had a low‑grade central osteosarcoma of the left tibia, was scheduled to receive three cycles of cisplatin and doxorubicin based on neoadjuvant chemotherapy, followed by surgery and later followed by three more cycles of cisplatin and doxorubicin based on adjuvant chemotherapy. He completed neoadjuvant chemotherapy and also underwent tumour resection as well as endoprosthesis application. Prior the administration of planned adjuvant therapy, he reported p